ATARA BIOTHERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (“Agreement”) is effective as of , 2014, by and between ATARA BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), dated as of October 22, 2012 (the “Amendment Effective Date”), is made by and between AMGEN INC., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and NINA BIOTHERAPEUTICS, INC., a Delaware corporation (“Licensee”).
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and SANTA MARIA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 7, 2012 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and SANTA MARIA BIOSCIENCES, INC., a Delaware corporation (“Company”). Company and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and PINTA BIOSCIENCES, INC. Dated as of September 7, 2012Supply Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 7, 2012 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and PINTA BIOSCIENCES, INC., a Delaware corporation (“Company”). Company and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), dated as of July 29, 2013 (the “Amendment Effective Date”), is made by and between AMGEN INC., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and SANTA MARIA BIOTHERAPEUTICS, INC., a Delaware corporation having an address of 3260 Bayshore Blvd, Brisbane, California 94005 (“Licensee”).
ATARA BIOTHERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”) is made and entered into as of March 31, 2014, by and between Atara Biotherapeutics. Inc., a Delaware corporation (the “Company”) and Isaac Ciechanover, M.D. (“Executive”). From and following the date hereof, this Agreement shall replace and supersede that certain letter agreement between the. Company and Executive dated September 6, 2012, as amended on October 22, 2012, and as further amended on December 5, 2012 (the “Prior Agreement”).
ATARA BIOTHERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”) is made and entered into as of March 31, 2014, by and between Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”) and Christopher M. Haqq, M.D., Ph.D. (“Executive”). From and following the date hereof, this Agreement shall replace and supersede that certain letter agreement between the Company and Executive dated September 12, 2012, as amended on December 5, 2012 (the “Prior Agreement”).
ATARA BIOTHERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”) is made and entered into as of March 31, 2014, by and between Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”) and Mitchall Clark (“Executive”). From and following the date hereof, this Agreement shall replace and supersede that certain letter agreement between the Company and Executive dated March 10th, 2014 (the “Prior Agreement”).
ContractStock Unit Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
The Company hereby awards Stock Units to the Participant named below. The terms and conditions of the Award are set forth in this cover sheet, in the attached Stock Unit Agreement and in the Plan. This cover sheet is incorporated into and a part of the attached Stock Unit Agreement (together, the “Agreement”).
SUBLEASE AGREEMENTSublease Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Sublease Agreement (herein the “Agreement”) is made and entered into by and among XDx, Inc., a Delaware Corporation (“Sublessor”) and Atara Biotherapeutics, Inc., a Delaware corporation (“Subtenant”) this 10th day of January 2013 to be effective as of the Commencement Date (as hereinafter defined).
AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), dated as of June 28, 2013 (the “Amendment Effective Date”), is made by and between AMGEN INC., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and PINTA BIOTHERAPEUTICS, INC., a Delaware corporation having an address of 3260 Bayshore Blvd, Brisbane, California 94005 (“Licensee”).
ATARA BIOTHERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”) is made and entered into as of March 31, 2014, by and between Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”) and Gad Soffer (“Executive”). From and following the date hereof, this Agreement shall replace and supersede that certain letter agreement between the Company and Executive dated February 1, 2013 (the “Prior Agreement”).
AMENDMENT NO. 3 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to the Exclusive License Agreement (this “Amendment”), dated as of April 4, 2014 (the “Amendment Effective Date”), is made by and between Amgen Inc., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and Santa Maria Biotherapeutics, Inc., a Delaware corporation having an address of 3260 Bayshore Blvd, Brisbane, California 94005 (“Licensee”).
AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), dated as of September 7, 2012 (the “Amendment Effective Date”), is made by and between AMGEN INC., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and NINA BIOTHERAPEUTICS, INC., a Delaware corporation having an address of 3260 Bayshore Blvd, Brisbane, California 94005 (“Licensee”).
ATARA BIOTHERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”) is made and entered into as of March 11, 2014, by and between Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”) and John McGrath (“Executive”). From and following the date hereof, this Agreement shall replace and supersede that certain letter agreement between the Company and Executive dated December 5, 2012 (the “Prior Agreement”).
CONSENT TO SUBLEASEConsent to Sublease • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This CONSENT TO SUBLEASE (this “Consent”) is entered into as of this 14th day of January, 2013, by and between BMR-BAYSHORE BOULEVARD LP, a Delaware limited partnership (“Landlord”), as successor in interest to BMR-Bayshore Boulevard LLC, XDX, INC., a Delaware corporation (“Tenant”), and ATARA BIOTHERAPEUTICS, INC., a Delaware corporation (“Subtenant”).
ATARA BIOTHERAPEUTICS, INC. INVESTORS’ RIGHTS AGREEMENT March 31, 2014Investors’ Rights Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 31st day of March, 2014, by and among Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor” and collectively as the “Investors”, and the holders of Common Stock (as defined below) listed on Schedule B hereto, each of which is herein referred to as a “Common Holder” and collectively as the “Common Holders”.
